Dublin, March 06, 2025 (GLOBE NEWSWIRE) -- The "PD-L1 Biomarker Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarkets ...

The global PD-L1 biomarker testing market is on a strong growth trajectory, rising from USD 777.2 million in 2025 to USD 1,690.8 million by 2035, at a CAGR of 8.1% during the forecast period. PD-L1 ...

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, March 06, 2025 (GLOBE NEWSWIRE) -- The "PD-L1 Biomarker Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has ...

私たち人間の体内では、日々、免疫システムが働き、ウイルスや細菌、がん細胞など、体に害を及ぼす異物から身を守って ...

EINPresswire/ -- "Get 20% Off All Global Market Reports With Code ONLINE20 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors What Is The Expected Cagr For The PD-L1 And ...

海外論文ピックアップ JAMA誌より JAMA Oncology誌から PD-1/PD-L1阻害薬に関する有害事象のまとめ 臨床試験の系統的レビューとメタアナリシス 2019/05/24 大西 淳子＝医学ジャーナリスト ...

PARSIPPANY, NJ--(Marketwired - Feb 3, 2016) - Diaceutics Group, a dedicated integrator in personalized and precision medicine, enabling the effective combination of therapies and diagnostics into the ...

非小細胞肺癌（NSCLC）における使用について、コンパニオン診断薬として承認を取得 PD-L1 IHC 22C3 pharmDx「ダコ」により、キイトルーダ(R)（一般名:ペムブロリズマブ）の 治療対象となるPD-L1陽性の切除不能な進行・再発の非小細胞肺癌の患者を特定 アジレント ...

Two viewpoint articles published in JAMA Oncology provide opposing opinions on the benefit of testing for programmed death-ligand 1 (PD-L1) expression in patients with non-small-cell lung cancer ...